ABN AMRO Fund
56
53M
48
1.70
13
0.14
21
- Stages of investment
- Areas of investment
Summary
In 1991 was created ABN AMRO Fund, which is appeared as VC. The fund was located in Europe if to be more exact in The Netherlands. ABN AMRO Fund appeared to be a CVC structure as part of the corporation. The main office of represented VC is situated in the Amsterdam.
The top amount of exits for fund were in 2009. Comparing to the other companies, this ABN AMRO Fund performs on 14 percentage points more the average number of lead investments. When the investment is from ABN AMRO Fund the average startup value is 10-50 millions dollars. The fund is constantly included in 2-6 investment rounds annually. The common things for fund are deals in the range of 50 - 100 millions dollars. The high activity for fund was in 2000. Speaking about the real fund results, this VC is 11 percentage points more often commits exit comparing to other organizations.
The fund was created by Bernard-Louis Roques.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the ABN AMRO Fund, startups are often financed by St. Paul Venture Capital, Granite Ventures, West Deutsche Landesbank Girozentrale. The meaningful sponsors for the fund in investment in the same round are Oxford Bioscience Partners, Forbion Capital Partners, Giza Venture Capital. In the next rounds fund is usually obtained by Forbion Capital Partners, Scottish Equity Partners, Oxford Bioscience Partners.
Among the most popular portfolio startups of the fund, we may highlight Cortera, AM Pharma, BioVex. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in a number of founders of portfolio startups. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Biotechnology, Information Technology.
Investments analytics
Analytics
- Total investments
- 56
- Lead investments
- 13
- Exits
- 21
- Rounds per year
- 1.70
- Follow on index
- 0.14
- Investments by industry
- Biotechnology (17)
- Health Care (12)
- Software (12)
- Medical (10)
- Pharmaceutical (9) Show 79 more
- Investments by region
-
- United Kingdom (8)
- United States (25)
- Spain (1)
- Netherlands (11)
- China (2) Show 6 more
- Peak activity year
- 2000
- Number of Unicorns
- 2
- Number of Decacorns
- 2
- Number of Minotaurs
- 3
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 21
- Avg. valuation at time of investment
- 58M
- Group Appearance index
- 0.93
- Avg. company exit year
- 10
- Avg. multiplicator
- 2.21
- Strategy success index
- 0.70
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Drug Abuse Sciences | 01 Mar 2001 | Biotechnology, Health Care, Medical | Early Stage Venture | 59M | United States, California |
In Ovo | 01 Mar 2022 | Biotechnology, Health Care, Sustainability, Veterinary | Early Stage Venture | 40M | South Holland, Leiden, Netherlands |
Planetoid Mines Corporation | 02 Aug 2018 | Aerospace, Space Travel, Mining | Seed | 150K | United States, New Mexico, Rio Rancho |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.